Evidence map›Paper›PMID 40220078›Full record

ReviewApplied microbiology and biotechnology2025

Mycotoxin-free Aspergillus oryzae strain lineage for alternative and novel protein production at industrial scale.

Jan Lehmbeck, Birgitte Andersen, Javier Sáez-Sáez, Jens Christian Frisvad, José Arnau

Abstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Computational and structural biotechnology journal · 2026
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jan Lehmbeck21,.BIO, Sydmarken 42, 2860, Søborg, Denmark.
Birgitte Andersen21,.BIO, Sydmarken 42, 2860, Søborg, Denmark.
Javier Sáez-Sáez21,.BIO, Sydmarken 42, 2860, Søborg, Denmark.
Jens Christian FrisvadDept. Biotechnology and Biomedicine, Technical University of Denmark, Søltoft Plads 221, 124, 2800, Lyngby, Denmark.
José Arnau21,.BIO, Sydmarken 42, 2860, Søborg, Denmark. j.arnau@21st.bio.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced industrial strains of Aspergillus oryzae have been used for decades for the production of recombinant proteins including food and feed enzymes at large scale. The A. oryzae strain lineage evaluated in this review derives from the proprietary Novozymes (now Novonesis) strain collection. A. oryzae wild-type strains have the potential to produce three different mycotoxins (aflatoxins (AFL), cyclopiazonic acid (CPA), and 3-nitropropionic acid (3-NPA)). Here, we review the work originally performed at Novozymes to identify a strain (BECh1) that contained a large chromosomal deletion comprising both AFL and CPA gene clusters, significantly improving the safety of the lineage. The description of the deleted region is presented here. As the genetic basis for 3-NPA biosynthesis was recently revealed, we describe here that this A. oryzae lineage contains an additional large deletion that encompasses the 3-NPA biosynthetic genes npaA and npaB, thereby rendering the strains unable to produce any mycotoxin. Further strain development has resulted in strains devoid of penicillin production by inactivation of the penicillin G gene cluster (penG). This strain lineage represents the first example of mycotoxin-free A. oryzae for production of recombinant (alternative) novel food proteins. Recently, bovine beta-lactoglobulin made using a strain of this lineage has received GRAS status and can be commercialized for use in food in the USA. With its history of safe use in food and feed, the lack of toxigenic potential and the ability to differentiate strains with modern technologies, this A. oryzae strain can be considered safe as other organisms with a Quality Presumption of Safety (QPS) status in Europe. QPS is not applicable to filamentous fungi and only granted at the species level to bacteria and a few yeast species. We suggest modernizing the QPS concept to become strain rather than species specific and present arguments to qualify this strain lineage as QPS or QPS-like. KEY POINTS: • The biosynthetic genes for 3-nitropropionic acid have been recently characterized. • An industrial strain lineage for food protein production lacks all known mycotoxin genes. • Proteins produced in this mycotoxin-free lineage should entail lower regulatory requirements.

Indexed as

Aspergillus oryzaeIndustrial MicrobiologyMycotoxinsRecombinant ProteinsAflatoxinsAnimalsGene DeletionIndolesMultigene FamilyNitro CompoundsPropionates3-nitropropionic acidAflatoxinscyclopiazonic acidIndolesMycotoxinsNitro CompoundsPropionatesRecombinant ProteinsAspergillus oryzaeMycotoxinNovel food proteinPrecision fermentationRegulatory approval

Identifiers

PMID40220078
PMCPMC11993488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.